DE60136648D1 - Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung - Google Patents

Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung

Info

Publication number
DE60136648D1
DE60136648D1 DE60136648T DE60136648T DE60136648D1 DE 60136648 D1 DE60136648 D1 DE 60136648D1 DE 60136648 T DE60136648 T DE 60136648T DE 60136648 T DE60136648 T DE 60136648T DE 60136648 D1 DE60136648 D1 DE 60136648D1
Authority
DE
Germany
Prior art keywords
fenretinide
retinide
pharmaceutical compositions
solvent
increased bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136648T
Other languages
English (en)
Inventor
Shanker Gupta
Barry James Maurer
C Patrick Reynolds
B Rao Vishnuvajjala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Application granted granted Critical
Publication of DE60136648D1 publication Critical patent/DE60136648D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60136648T 2000-12-05 2001-12-05 Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung Expired - Lifetime DE60136648D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25146300P 2000-12-05 2000-12-05
PCT/US2001/046548 WO2002058689A1 (en) 2000-12-05 2001-12-05 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same

Publications (1)

Publication Number Publication Date
DE60136648D1 true DE60136648D1 (de) 2009-01-02

Family

ID=22952077

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136648T Expired - Lifetime DE60136648D1 (de) 2000-12-05 2001-12-05 Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung

Country Status (8)

Country Link
US (1) US7169819B2 (de)
EP (1) EP1349545B1 (de)
JP (2) JP4384409B2 (de)
AT (1) ATE414511T1 (de)
DE (1) DE60136648D1 (de)
DK (1) DK1349545T3 (de)
ES (1) ES2316489T3 (de)
WO (1) WO2002058689A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069203A2 (en) * 2003-01-31 2004-08-19 Childrens Hospital Los Angeles Research Institute Oral compositions of fenretinide having increased bioavailability and methods of using the same
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
BRPI0405798B8 (pt) * 2003-11-28 2021-05-25 Halex Istar Ind Farmaceutica L processo de eliminação de resíduos alcalinos presentes no 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amino-1h-purin-6(9h)-ona e apresentação farmacêutica
EA011864B1 (ru) * 2004-06-23 2009-06-30 Сирион Терапьютикс, Инк. Применение 4-гидроксифенилретинамида и 4-метоксифенилретинамида для лечения офтальмологических состояний
EP1804788A4 (de) * 2004-10-25 2008-05-21 Sirion Therapeutics Inc Detektion und analyse von ophthalmisch relevanten, fluoreszierenden molekülen
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US7321064B1 (en) 2007-03-08 2008-01-22 Cedarburg Pharmaceuticals, Inc. Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates
WO2009045345A1 (en) * 2007-09-28 2009-04-09 Childrens Hospital Los Angeles Research Institute Metabolic degradation inhibitors for anti-hyperproliferative agents
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8642658B2 (en) 2008-02-21 2014-02-04 Royal Institution For The Advancement Of Learning/Mcgill University Treatment of neural diseases or conditions
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
EP2174650A1 (de) * 2008-10-08 2010-04-14 Polichem SA Modifizierte Freisetzungsemulsionen zur Anwendung auf der Haut und der Vaginalschleimhaut
EP2501672A4 (de) 2009-11-12 2013-05-01 Univ Texas Tech Zusammensetzungen und verfahren zur behandlung hyperproliferativer erkrankungen
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US20120121691A1 (en) * 2010-11-15 2012-05-17 Texas Tech University System Method for Increasing the Production of a Specific ACYL-Chain Dihydroceramide(s) for Improving the Effectiveness of Cancer Treatments
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
AU2015292212B2 (en) 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2022170398A1 (en) * 2021-02-11 2022-08-18 Monash University Formulations for improved bioavailability of fenretinide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
DE3432696A1 (de) * 1984-09-03 1986-03-13 Siemens AG, 1000 Berlin und 8000 München Antriebsvorrichtung fuer einen leistungsschalter mit exzenter und richtgesperre
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4960799A (en) 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
DE69109297T2 (de) * 1990-08-13 1995-11-09 David W. Byfield Mass. Yesair Gemischte lipid-bicarbonat-kolloidale partikel zur abgabe von arzneien und kalorien.
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
EP0671953A4 (de) 1992-11-13 1996-01-10 Univ Ohio State Res Found C-glycosid-analoge des n-(hydroxyphenyl)retinamid-o-glucuronids.
US5464870A (en) 1993-02-10 1995-11-07 Ortho Pharmaceutical Corporation Methods of inhibiting development of leukoplakia with fenretinide
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE69614855T2 (de) * 1995-06-06 2002-03-28 Biomolecular Products Inc Gemischte lipid-bicarbonat kolloidale partikel zur abgabe von arzneistoffen oder kalorien
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BE1011216A3 (fr) 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
ES2316188T3 (es) * 1998-06-29 2009-04-01 Children's Hospital Los Angeles Tratamiento de transtornos hiperproliferativos.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2002211776A1 (en) * 2000-10-17 2002-04-29 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes

Also Published As

Publication number Publication date
JP2005510447A (ja) 2005-04-21
WO2002058689A1 (en) 2002-08-01
US20020183394A1 (en) 2002-12-05
ES2316489T3 (es) 2009-04-16
EP1349545A4 (de) 2006-05-24
JP2009292834A (ja) 2009-12-17
US7169819B2 (en) 2007-01-30
DK1349545T3 (da) 2009-02-16
EP1349545A1 (de) 2003-10-08
ATE414511T1 (de) 2008-12-15
EP1349545B1 (de) 2008-11-19
JP4384409B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
DE60136648D1 (de) Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
Kawakami et al. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents
EA200601460A1 (ru) Препарат микроэмульсии с высокой концентрацией пропофола для анестезирующих применений
Alvarez-Núñez et al. Relationship between Polysorbate 80 solubilization descriptors and octanol–water partition coefficients of drugs
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
Kawakami et al. Solubilization behavior of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent
MXPA05013278A (es) Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
Radomska et al. The use of some ingredients for microemulsion preparation containing retinol and its esters
ATE153532T1 (de) Zusammensetzungen, die einen fluorokohlenwasserstoff und eine lipophile/fluorophile organische verbindung enthalten und ihre verwendungen
KR950007872A (ko) 안정화된 약제학적 조성물 및 안정화용매
AU775158B2 (en) Water-miscible pharmaceutical compositions of paclitaxel
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
DE69522227T2 (de) Öl-im-wasser-emulsionen enthaltend taxin (taxol) und verfahren
TR199500299A2 (tr) Farmasötik bilesimler.
PT989851E (pt) Formulacao auto-emulsionante para compostos lipofilicos acidicos
CA2716576A1 (en) Fulvestrant formulations
ATE398997T1 (de) Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
EA200600528A1 (ru) Способ получения водорастворимых дитерпенов и их применение
DE60119082D1 (de) Anästhetikum enthaltende formulierungen
SE0000774D0 (sv) New formulation
Altamimi et al. Enhanced skin permeation of hydrocortisone using nanoemulsion as potential vehicle
DE60103865D1 (de) Arzneizubereitungen und deren herstellungsverfahren
Correa et al. On the incorporation of the non-steroidal anti-inflammatory naproxen into cationic O/W microemulsions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition